HHS Envisions Drug Price Arbitration For Part D
This article was originally published in The Pink Sheet Daily
Approaches for HHS to become involved in drug price negotiations between Medicare Part D plan sponsors and manufacturers were outlined by HHS Assistant Secretary for Planning and Evaluation Richard Frank at a policy conference, although current law would need to be revised to allow it.
You may also be interested in...
Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?
President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.
HHS Raises Profile In Drug Costs Discussion
On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.
Pricing, Pediatrics, Pot: 21st Century Cures Amendments
Committee members didn’t even vote on any amendments besides the manager’s package, but proposals floated and withdrawn offer glimpse at potential fights to come.